Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Natalie Uy, Abhay Singh, Steven D. Gore & Thomas Prebet. (2017) Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opinion on Pharmacotherapy 18:12, pages 1213-1224.
Read now
Read now
Abdallah Abou Zahr, Carolina Bernabe Ramirez, Jocelyn Wozney, Thomas Prebet & Amer M. Zeidan. (2016) New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Expert Review of Hematology 9:4, pages 377-388.
Read now
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now
Read now
Articles from other publishers (14)
Kristína Šimoničová, Lubos Janotka, Helena Kavcova, Zdena Sulova, Lucia Messingerova & Albert Breier. (2023) Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol. Cancers 15:11, pages 3063.
Crossref
Crossref
Hussein Awada, Carmelo Gurnari, Zhuoer Xie, Jan Philipp Bewersdorf & Amer M. Zeidan. (2023) What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 15:8, pages 2248.
Crossref
Crossref
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri & Guillermo Garcia‐Manero. (2022) A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. American Journal of Hematology 98:2, pages 272-281.
Crossref
Crossref
Maria R. BaerAksinija A. KoganSøren M. BentzenTian Mi, Rena G. LapidusVu H. DuongAshkan EmadiSandrine NiyongereCasey L. O'Connell, Benjamin A. YoungbloodStephen B. Baylin & Feyruz V. Rassool. (2022) Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. Clinical Cancer Research 28:7, pages 1313-1322.
Crossref
Crossref
Kristína Šimoničová, Ľuboš Janotka, Helena Kavcová, Zdena Sulová, Albert Breier & Lucia Messingerova. (2022) Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resistance Updates 61, pages 100805.
Crossref
Crossref
Guangjie Zhao, Qian Wang, Shuang Li & Xiaoqin Wang. (2021) Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism. Frontiers in Oncology 11.
Crossref
Crossref
Julia Stomper, John Charles Rotondo, Gabriele Greve & Michael Lübbert. (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35:7, pages 1873-1889.
Crossref
Crossref
Pasquale Niscola, Carmen Di Grazia, Carla Mazzone, Barbara Tolu, Paolo de Fabritiis & Emanuele Angelucci. (2019) Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation. BLOOD RESEARCH 54:4, pages 288-290.
Crossref
Crossref
Jan Stratmann, Elisabeth van Kann, Christoph Rummelt, Sebastian Koschade, Christoph Röllig, Michael Lübbert, Markus Schaich, Stefani Parmentier, Martin Sebastian, Joerg Chromik, Aaron Becker von Rose, Olivier Ballo, Björn Steffen, Hubert Serve, Christian Brandts & Shabnam Shaid. (2019) Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leukemia Research 85, pages 106192.
Crossref
Crossref
Richard Daifuku. 2019. Pharmacoepigenetics. Pharmacoepigenetics
425
435
.
Thomas Schroeder, Christina Rautenberg, William Krüger, Uwe Platzbecker, Gesine Bug, Juliane Steinmann, Stefan Klein, Olaf Hopfer, Kathrin Nachtkamp, Mustafa Kondakci, Stefanie Geyh, Rainer Haas, Ulrich Germing, Martin Bornhäuser & Guido Kobbe. (2017) Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Annals of Hematology 97:2, pages 335-342.
Crossref
Crossref
Rama Nanah, Kristen McCullough, William Hogan, Kebede Begna, Mrinal Patnaik, Michelle Elliott, Mark Litzow & Aref Al-Kali. (2017) Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. American Journal of Hematology 92:9, pages 866-871.
Crossref
Crossref
Daniel A. Roberts & David P. Steensma. (2015) Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Current Hematologic Malignancy Reports 10:3, pages 318-328.
Crossref
Crossref
Stéphanie Harel, Amina Cherait, Céline Berthon, Christophe Willekens, Sophie Park, Marthe Rigal, Sabine Brechignac, Sylvain Thépot, Bruno Quesnel, Claude Gardin, Lionel Adès, Pierre Fenaux & Thorsten Braun. (2015) Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research 39:5, pages 501-504.
Crossref
Crossref